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Abstract
Background
Cancers of the oral cavity are primarily oral squamous cell carcinomas (OSCCs). Many of
the OSCCs present at late stages with an exceptionally poor prognosis. A probable limita-
tion in management of patients with OSCC lies in the insufficient knowledge pertaining to
the linkage between copy number alterations in OSCC and oral tumourigenesis thereby
resulting in an inability to deliver targeted therapy.
Objectives
The current study aimed to identify copy number alterations (CNAs) in OSCC using array
comparative genomic hybridization (array CGH) and to correlate the CNAs with clinico-path-
ologic parameters and clinical outcomes.
Materials and methods
Using array CGH, genome-wide profiling was performed on 75 OSCCs. Selected genes
that were harboured in the frequently amplified and deleted regions were validated using
quantitative polymerase chain reaction (qPCR). Thereafter, pathway and network functional
analysis were carried out using Ingenuity Pathway Analysis (IPA) software.
Results
Multiple chromosomal regions including 3q, 5p, 7p, 8q, 9p, 10p, 11q were frequently ampli-
fied, while 3p and 8p chromosomal regions were frequently deleted. These findings were in
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confirmation with our previous study using ultra-dense array CGH. In addition, amplification
of 8q, 11q, 7p and 9p and deletion of 8p chromosomal regions showed a significant correla-
tion with clinico-pathologic parameters such as the size of the tumour, metastatic lymph
nodes and pathological staging. Co-amplification of 7p, 8q, 9p and 11q regions that har-
bored amplified genes namely CCND1, EGFR, TPM2 and LRP12 respectively, when com-
bined, continues to be an independent prognostic factor in OSCC.
Conclusion
Amplification of 3q, 5p, 7p, 8q, 9p, 10p, 11q and deletion of 3p and 8p chromosomal regions
were recurrent among OSCC patients. Co-alteration of 7p, 8q, 9p and 11q was found to be
associated with clinico-pathologic parameters and poor survival. These regions contain
genes that play critical roles in tumourigenesis pathways.
Introduction
Globally, oral and oropharyngeal cancer is ranked as the sixth most common cancer with an
estimated 300,000 new cases being reported in 2012 [1]. Although globally oral cancer is a
male-predominant disease [2], incidence of oral cancer in Malaysia varies according to gender
and ethnicity [3]. According to the National Cancer Registry Statistics in Malaysia, there was a
higher incidence of oral cancer reported in Indian and Malay females. In contrast, for the Chi-
nese population, there was a high oral cancer incidence in males. The higher prevalence of oral
cancer in Indian female population may be related to the predominant lifestyle habits such as
betel quid chewing [4] among this group. Despite the advances in diagnosis and therapeutic
approaches, the mortality and morbidity rates have not improved over the past decades [5].
Copy number alterations promote genetic instability in cancer and lack of improvement in the
clinical outcomes most probably reflects the paucity in the knowledge that explains how
genetic instabilities in oral cancer contribute in oral carcinogenesis [6, 7]. Moreover, molecular
heterogeneity is another issue that should be kept in mind [8].
Oral carcinogenesis is a complex process, resulting from a multistep pathway with accumu-
lation of genetic alterations [7]. Copy number alterations (CNAs) that include amplifications
and deletions result in activation of proto-oncogenes and inactivation of tumour suppressor
genes, respectively [9]. Several recurrent CNAs have been reported in OSCC by many authors
[10–13], but how these CNAs play a role in the pathogenesis of OSCC has not been thus far
elucidated. Profiling of CNAs using high-throughput methods provides advanced tools to dis-
cover potential biomarkers that could be used for predictive, prognostic and diagnostic
approaches [14, 15].
The pattern of CNAs as biomarkers have remarkable significance due to their great impact
related with diseases outcome and personalized medicine [15]. Therefore, the identification of
the effective biomarkers for prognosis and diagnosis is an early step in the plan for molecular
sub-classification that underlies the pathophysiology of the disease. These specific molecular
classifications may have the potential to predict early disease and in deciding the patient’s
treatment including personalized medicine (targeted gene therapy) [15]. Cervical lymph node
metastasis (LNM) is a predictor of poor prognosis in OSCC [16, 17]. The ability to accurately
predict lymph node metastases in OSCC patients will enable the clinician to plan the appropri-
ate treatment. However, the CNAs in OSCC and its association with clinico-pathological
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parameters and clinical outcome remain undetermined. Hence, we aimed to identify recurrent
CNAs and their clinical and prognostic impacts in OSCC using high-resolution array CGH.
High-resolution array CGH could aid in the identification of candidate genes/regions that
may drive the development of oral cancer.
Materials and methods
In this study, tumour samples selected were SCCs derived from within the oral cavity consist-
ing of the anterior two-thirds of the tongue, the buccal mucosa, alveolar ridge, lip, floor of the
mouth and hard palate (C00, 02–06) and excluded the base of tongue (C01) and other head
and neck sites such as oropharynx, hypopharynx and larynx due to their varied etiologic,
genetic, clinical characteristics and prognosis [18, 19]. For example, the principal etiological
factors for oral cancer are tobacco smoking, alcohol drinking and betel quid chewing whereas
majority of the oropharyngeal cancers are HPV-related. Apart from that, Chung et al. [20]
observed that OSCC is more heterogeneous in terms of their genetic and molecular expression
as compared to squamous cell carcinomas derived from other head and neck regions (oro-
pharynx, hypopharynx, and larynx). In view of this, we have grouped OSCC of all these sub-
sites (C00, C02-06) as a single oral cancer site in this current study.
Tumour samples
A total of 75 OSCC fresh-frozen tissue samples were included for the genome wide array CGH
analysis. Sixty-six overlapping OSCC samples were used for validation of the CNAs that resulted
from array CGH data using quantitative real-time PCR analysis. Fresh-frozen OSCC tissue sam-
ples and the related socio-demographic (risk habits, gender, age group) and clinico-pathologic
data (site of lesion, tumour size, lymph node status and tumour staging) were acquired from the
Malaysian Oral Cancer Database and Tissues Bank System (MOCDTBS) coordinated by the
Oral Cancer Research and Coordinating Centre, University of Malaya [21]. All the OSCC sam-
ples recruited in this study had been tested for infection with Human papillomavirus (HPV) 16
and 18 using the HPV GenoArray (Hybribio Ltd, Hong Kong) and all were found to be negative
for both types (unpublished data). The socio-demographic and clinico-pathologic parameters
of the OSCC samples are listed in Table 1. The International Classification of Disease (ICD-10),
developed by World Health Organization (WHO) was used to categorize the OSCC samples
according to the anatomical subsites. Tumour staging was done according to the criteria by The
American Joint Committee on cancer staging [22]. All the OSCC samples that were included in
this study were histologically confirmed by oral pathologists. Approval for this study was
granted by the Medical Ethics Committee (MEC), Faculty of Dentistry, University of Malaya
vide MEC code no: DF0306/ 001/(L) and DF OS1007/0048(P). All the methodology employed
in this study was in accordance with International Conference on Harmonisation–Good Clini-
cal Practice (ICH-GCP) guideline for good clinical practice and the Declaration of Helsinki.
Histopathology and array CGH analysis
Histological assessment was carried out on haematoxylin and eosin (H&E) stained frozen tis-
sue specimens mounted in optimal cutting temperature (OCT) compound. The sections were
analysed to determine percentage of tumour content. Tissues that did not contain 70% tumour
were macro-dissected to gain areas with 70% of tumour content for DNA extraction. Extrac-
tion of DNA was carried out using DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions.
A customized array CGH platform was designed for OSCC based on our previous research
[11, 23] and previously reported candidate regions/genes for OSCC. This customized
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oligonucleotide array CGH (8x60k) was manufactured by Agilent Technologies, CA, USA.
Thereafter, genome-wide profiling was completed based on the manufacturer’s instructions
(version 5.0, June 2007) by Oxford Gene Technology, Oxford, UK. Genomic DNA of tumour
samples was fragmented by enzymatic digestion. Subsequent steps included sample labelling,
probe purification, microarray hybridization, washing and scanning. For each array CGH profil-
ing, 1.5 μg of DNA (gDNA) from each of the test samples and commercially obtained gender
matched pooled blood gDNA sample (Promega Corporation, WI, USA) were obtained and
labelled with fluorescence Cy5 and Cy3 dyes in dye-swap protocol using the CytoSure Genomic
DNA labelling kit (Oxford Gene Technology, Oxford, UK), respectively. Probe purification was
done using Microcon YM-30 filters (Merck Millipore, MA, USA). This was followed by probe
denaturation and pre-annealing with Cot-1 DNA. Constant rotation at 20 rpm (65˚C for 40
hours) completed the hybridization process. Slides were washed after the hybridization process
conforming to the manufacturer’s instructions and scanned using a DNA Microarray Scanner
(Agilent Technologies, CA, USA). Feature Extraction software, version 10.7.3.1 (Agilent Tech-
nologies, CA, USA) was used to generate the signal intensities in the text file per array. The data
from the text file was segmented using a modified Circular Binary Segmentation (CBS) algo-
rithm [24]. The CNAs were recognized using CytoSure Interpret software version 4.2.5 (Oxford
Gene Technology, Oxford, UK) based on the application of log2 intensity ratios of sample to ref-
erence (Cy3/Cy5: log2-ratios above 0.3 for amplifications and below -0.6 for deletions). CNAs
genomic positions (start and end) along with list of cytobands were annotated based on the
human genome assembly version GRCh37/hg19. The microarray data have been deposited in
Table 1. Socio-demographic and clinico-pathologic parameters of the 75 OSCC cases involved in
array CGH study.
Variables Category No. of patients (%)
Total 75
Gender Male 26 (34.7)
Female 49 (65.3)
Age (years) < 45 12 (16.0)
 45 63 (84.0)
Smoking No 52 (69.3)
Yes 23 (30.7)
Drinking No 64 (85.3)
Yes 11 (14.7)
Betel quid chewing No 40 (53.3)
Yes 35 (46.7)
Tumour site Tongue 24 (32.0)
Non-tongue* 51 (68.0)
Tumour size T1-T2 45 (60.0)
T3-T4 30 (40.0)
Lymph node metastasis Negative 38 (50.7)
Positive 37 (49.3)
pTNM Staging Early stage 26 (34.7)
Advanced stage 49 (65.3)
Overall survival Range 1–114 months
Median 21.0 months
Mean 26.24 months
* Non-tongue = Buccal mucosa, gingiva, lip, floor of mouth and plate
https://doi.org/10.1371/journal.pone.0174865.t001
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the Gene Expression Omnibus (GEO) database with the accession number of GSE89924. CNAs
were classified irrespective of the sizes which may have gene-rich regions with possibility of
being pathogenic. CNAs with closest overlap regions and their redundancies with in each cyto-
band were considered to calculate frequency of amplification and/or deletions. Overall percent-
ages were calculated by dividing the frequency of amplification and/or deletion in each cytoband
by total number of CNAs identified. Cytobands were ranked according to the percentage, a cut-
off of 8% was applied to highlight significant CNAs and also focus on highly altered genes in
CNA. Significant CNAs identified by above cutoff were compared to data from The Cancer
Genome Atlas (TCGA) [25] and International Cancer Genome Consortium (ICGC) [26].
Pathway and network analysis
The annotated genes within the copy number altered regions that had a frequency of 8% were
subjected to gene pathway/network and biological function (diseases, molecular and cellular
functions) analysis using Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems, CA,
USA). The default setting from the software was used to map the CNA associated genes to the
reference set of direct and indirect relationships. Next, relevant input to the gene list such as
the molecular networks and biological functions were generated by the software algorithm.
The significance of the gene annotation with a p-value less than 0.05 was determined with
right-tailed Fisher’s exact test.
Copy number analysis by the TaqMan PCR assay
Copy number analysis was done on 66 OSCCs using TaqMan Copy Number Assay: LRP12
(Hs01987319_cn), FSCN1 (Hs03631914_cn), EGFR (Hs02309320_cn), CCND1
(Hs02226007_cn), CHL1 (Hs02163529_cn), TPM2 (Hs01060645_cn), CLPTM1L
(Hs01133209_cn), CSMD1 (Hs03683117_cn) (Applied Biosystems, Foster City, CA, USA).
The commercially male and female-pooled blood gDNA samples (Promega Corporation, WI,
USA) served as calibrator controls. PCR was done in a total volume of 20 μl consisting of 4 μl
of genomic DNA(5 ng/μl), 10 μl of 2× TaqMan1 Genotyping Master Mix (Applied Biosys-
tems, CA, USA), 1 μl of 20X TaqMan Copy number assay, 1 μl of 20X TaqMan copy number
reference assay (RNAse P) and 4 μl of nuclease free water. Quantitative PCR was performed
on an ABI 7500 Fast Real Time PCR System (Applied Biosystems, CA, USA) using the manu-
facturer’s PCR conditions as follows: initial denaturation at 95˚C for 10 minutes followed by
40 cycles of denaturation for 15 seconds at 95˚C and annealing for 60 seconds at 60˚C.
The values of copy number for each sample were normalized using RNAase P as a reference
control with 2 copies in the human genome. Copy number was quantified using the equation
2 x (2−ΔΔCt), comparative CT (ΔΔCT) relative quantitation method [27]. Target and reference
assays that were used for copy number calculation were derived from the mean of triplicate,
RNase P and the calibrator samples. The calculated relative quantity was multiplied by a base
copy number of 2 to obtain the copy number value. The copy number of selected CNA associ-
ated genes were then classified into three groups, deletion (< 1.0), amplification (> 2.0 copies)
and no change (> 1.0 and 2.0 copies) [28, 29].
Selection of the cut-off point for LRP12, FSCN1, EGFR, CCND1, CHL1,
TPM2, CLPTM1L, CSMD1 genes
The clinico-pathologic data was first dichotomized based on the survival status of the OSCC
patients (alive vs dead). Receiver operating characteristic (ROC) curve analysis was used to
determine the best cut-off score for LRP12, FSCN1, EGFR, CCND1, CHL1, TPM2, CLPTM1L
and CSMD1 genes copy number to survival status using 0, 1 criterion [30]. For copy number
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alterations (scores) of the LRP12, FSCN1, EGFR, CCND1, CHL1, TPM2, CLPTM1L and
CSMD1 genes, the sensitivity and specificity of each score was plotted to generate various area
under the ROC curves (AUC) against survival status (alive vs dead). The score that was closest
to the point with maximum sensitivity and specificity was selected as the cut-off value. The
copy number alteration scores were divided into amplifications/deletions and no change
where no change was the score below or equal to the cut-off value, while amplifications/dele-
tions were the scores above the cut-off value.
Statistical analysis
The chi-square (or Fisher exact where appropriate) statistic was used to test the associations
between the selected CNAs (amplification of chromosome 3q, 8q, 7p, 9p, 11q and deletion of
3p and 8p) and clinico-pathologic parameters. The Mann-Whitney U test was used to compare
copy number changes of the candidate genes (LRP12, FSCN1, EGFR, CCND1, CHL1, TPM2,
CLPTM1L, CSMD1) between OSCC and non-cancer tissues. The Kaplan-Meier analysis was
used to ascertain the prognostic significance of these CNAs and candidate genes of the chro-
mosomes studied. In order to further test whether any of the selected CNAs and the associated
genes which showed significant association from the Kaplan-Meier analysis, the Multivariate
Cox Regression analysis was further employed. All statistical analyses were performed using
the SPSS statistical package (SPSS version 12.0, IL, USA) and the p-values < 0.05 was consid-
ered significant.
Results
Copy number alterations
The regions with a frequency of copy number alterations that was 8% were reported in this
study. In array CGH analysis, 26 amplified and 3 deleted chromosomal regions were found
(Table 2 and Fig 1). The number of occurrences, size of the start genome position and end
genome position of the CNAs are illustrated in Table 2. In the whole genome wide profiling
dataset, amplifications outnumbered deletions. Amplifications in 3q, 5p, 7p, 8q, 9p, 10p, 11q
and deletions in 3p and 8p chromosomal regions were recurrent. Amplification in 8q22.3-q23.1
and deletion in 3p21.31 were the most common findings, accounting for 18.7% and 9.3% of all
samples, respectively (Table 2). Chromosomal regions 3q, 8q and 11q depicted the largest num-
ber of CNAs (Table 2 and Fig 1). There were 11 and 21 CNAs identified from the current study
that shared similarities with the TGCA of the oral cancer array CGH OSCC study and the Inter-
national Cancer Genome Consortium (ICGC) respectively (Fig 2 and S1 Table).
Association of the copy number alterations with clinico-pathologic
parameters
Amplification of the chromosome 7p was significantly associated with both the tumour size
(T1-T2: 31.1% vs T3-T4: 70%, p = 0.001) and staging (early stages: 26.9% vs advanced stages:
57.1%, p = 0.013). Amplification in the long arm of chromosome 8 (early stage: 15.4% vs
advanced stages: 51.1%, p = 0.003), and 11 (early stages: 7.7% vs advanced stages: 28.6%,
p = 0.036) was associated with staging. In addition, deletion in the short arm of the chromo-
some 8 was found to be significantly associated with pathologic staging, (early stages: 11.5% vs
advanced stages: 38.8%, p = 0.014). Amplification in the short arm of chromosome 9 was sig-
nificantly associated with lymph node metastasis (LNM negative: 5.3% vs LNM positive:
24.3%, p = 0.02) (Table 3). The association of amplification of chromosomes 7p, 8q, 9p and
11q with the size of the tumour, metastatic lymph nodes and pathological staging prompted us
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to combine these CNAs as a genetic signature to increase clinical significance in OSCC
patients. Co-amplification of 1 of these CNAs within the genetic signature were found to be
associated with tumour sizes (T1-T2: 55.6% vs T3-T4: 83.3%, p = 0.012), lymph node metasta-
sis (LNM negative: 52.6% vs LNM positive: 81.1%, p = 0.009) and pathologic staging (early
stages: 42.3% vs advanced stages: 79.6%, p = 0.001) (Table 3).
Association of the copy number alterations with clinical outcomes
Three-year survival rates for amplification and non-amplification of all chromosomes are
summarized in S2 Table. Using Kaplan Meier analysis (Fig 3), amplification of chromosomes
7p, 8q, 9p, 11q and deletion of 8p was significantly associated with poor prognosis. However,
after using multivariate analysis and controlling for other confounders (after adjustment for
selected socio-demographic and clinico-pathologic data), all associations obtained in the
Kaplan Meier analysis were not significant except for chromosome 11 (S3 Table). Thus, only
chromosome 11q can be accepted as an independent prognostic marker based on the Multi-
variate analysis (S3 Table).
Table 2. Amplified and deleted regions detected in 75 OSCC samples.
Cytoband Median start position Median end position CNAs (AMP/DEL) Number of sample Percentage % (n = 75)
8q22.3-q23.1 102681371 109392898 AMP 14 18.7
7p11.2 54033427 56399307 AMP 12 16
8q12.1 57356305 61290015 AMP 11 14.7
5p13.2-p13.1 34263518 42496863 AMP 11 14.7
9p21.1-p13.3 30940311 35689407 AMP 11 14.7
8q21.13-q21.2 48435432 57172822 AMP 10 13.3
7p22.1-p11.2 7091279 55728080 AMP 9 12
8q11.21-q12.1 48435432 102647978 AMP 9 12
5p13.3-p13.2 31085740 34171734 AMP 9 12
11q13.1-q13.2 63411714 67465752 AMP 9 12
8q23.1-q24.11 48435432 51961330.5 AMP 9 12
8q24.13 48435432 146301585 AMP 8 10.7
8q24.3 49084980 54788562 AMP 8 10.7
3q13.32-q21.2 117659990 125404921 AMP 7 9.3
8q21.2-q21.3 49084980 52283007 AMP 7 9.3
7p22.3-p22.1 16324 5554669 AMP 7 9.3
5p13.1 38651455 40760663 AMP 7 9.3
11q13.3-q13.4 69592775 71296836 AMP 7 9.3
3q25.31-q26.1 156865802 162501514 AMP 7 9.3
3q27.3-q28 186822642 189711307 AMP 7 9.3
8q24.12-q24.13 57804398 61290015 AMP 6 8
11q13.3 68889918 69589223.5 AMP 6 8
11q13.4 71627053 74357770 AMP 6 8
10p13-p12.2 17275747.5 22617571 AMP 6 8
3q21.2-q26.1 125683802 162501514 AMP 6 8
3q26.1-q26.31 164035254 174942968.5 AMP 6 8
3p21.31 47076499 49558487 DEL 7 9.3
3p26.3-p26.1 64052 5256910 DEL 7 9.3
8p23.2 3680600 3841195 DEL 6 8
https://doi.org/10.1371/journal.pone.0174865.t002
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When amplification of any 1 or more ( 1) of the chromosomes 7p, 8q, 9p, 11q was consid-
ered, both Kaplan-Meier (Fig 3) and Multivariate Cox regression analysis (S3 Table) revealed
that co-amplification of 1 of these CNAs within the genetic signature was found to be associ-
ated with poor prognosis (HRR = 3.554, 95% C1 1.161–10.886, p = 0.026) after adjustment for
selected socio-demographic and clinico-pathologic data of OSCC (S2 Table). This result
showed that in addition to amplification of chromosome 11, co-amplification of 1 of these
CNAs within the genetic signature is also an independent prognostic marker.
TaqMan copy number assay of LRP12, TPM2, EGFR, FSCN1, CCND1,
CLPTM1L, CHL1 and CSMD1
Several candidate genes within the chromosomal regions that showed changes in the copy num-
ber were validated using qPCR analysis (Fig 4). Out of 26 samples that showed amplification of
chromosome 8q22.3 (LRP12) in array CGH, 13 (50%) samples showed amplification in the
qPCR copy number assay validation. Approximately 50% (7/14), 54.5% (6/11), 59.4%, 71.9%
and 75% of the samples that showed amplification in array CGH analysis for CCND1 (chromo-
some 11q13.3), TPM2 (chromosome 9p13.3), FSCN, EGFR (chromosome 7p11.2) and
CLPTM1L (chromosome 5p15.33) respectively were validated in qPCR copy number analysis.
As for the deletion CNAs, approximately 33.3% (7/21) and 36.8% (7/19) of the samples that
showed deletions in array CGH analysis for CSMD1 (chromosome 8p23.2) and CHL1 (chro-
mosome 3p26.3) respectively were validated in qPCR copy number analysis (Fig 4).
Fig 1. The ideogram of amplifications and deletions identified in this study using array CGH.
https://doi.org/10.1371/journal.pone.0174865.g001
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The chi-square analysis results showed that LRP12, TPM2, EGFR, FSCN1, CCND1,
CLPTM1L, CHL1 and CSMD1 genes were not associated with socio-demographic and clin-
ico-pathologic parameters. Additionally, Kaplan-Meier survival analysis did not show statisti-
cal significance between LRP12, TPM2, FSCN1, CCND1, CLPTM1L, CHL1 and CSMD1
genes and poor prognosis. Only amplification of the EGFR showed a trend towards association
with poor prognosis (p = 0.060). Moreover, the combination of four candidate genes namely
EGFR, LRP12, TPM2 and CCND1 located on 7p, 8q, 9p and 11q respectively were subjected
to the statistical analysis. The combined AUC for all the markers was 0.621 which is higher
than the single genetic markers. The OSCC patients were divided into two groups (Group 1 &
2). Group 1 included those patients who had a cumulative score of 0 markers while those with
a cumulative score of 1, 2, 3, or 4 markers were placed under group 2. A significant difference
between groups 1 and 2 (p = 0.045) (Fig 5) was observed in the Kaplan-Meier survival curves.
It was also observed that the 4 combined genetic markers remained as an independent prog-
nostic factor with a hazard risk ratio (HRR = 2.34) towards death in patients with amplification
of 1 or more markers after adjustment for socio-demographic and clinico-pathologic parame-
ters (Table 4) using Cox regression multivariate model.
Pathway and network analysis
The top significant signaling pathway revealed by IPA analysis was identified as integrin-
linked kinase signaling pathway (Table 5). Five different groups of molecular and cellular func-
tions were identified and included cell death and survival, cellular function and maintenance,
Fig 2. The ideogram of CNAs identified representing intersection of cytoband CNAs from TCGA and ICGC studies.
https://doi.org/10.1371/journal.pone.0174865.g002
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cellular development, cellular growth and proliferation, and cellular movement. Table 6 shows
the top three molecular and cellular functions that were associated with amplified and deleted
genes. They were cell death and survival, cellular function and maintenance that were mostly
associated with colony survival of cells (p = 8.72E-05) through contributions of ATR, CA9,
CCND1, FANCG, RAD21, RB1CC1, TERC and TNFSF10 genes. IPA analysis also revealed
that there were 26 genes associated with head and neck SCC. These 26 genes were MALAT1,
MRC1, POLQ, CCND1, SOX17, LIFR, FGF4, mir-15, FGF3, SHANK2, RAD21, EGFR,
FGF19, PPFIA1, TPCN2, MECOM, ANO1, ORAOV1, FADD, DDX58, EPPK1, LYN, ATR,
SETD2, MYEOV and CTTN. Network analysis on 1427 genes linked to CNA identified corre-
lation in the most remarkable network with cell death and survival, cellular movement and cel-
lular development (Table 7). This significant network harbored 73 genes and between them,
the major centers (cores) like CCND1, RELA, TP63 and EGFR formed interconnected auto-
regulatory and feed forward circuitry in the network (S1 Fig). The main function of this net-
work involved tumour growth and proliferation by evasion of apoptosis signals thereby pro-
moting cell survival and metastasis.
Fig 3. Overall survival curves were analyzed according to amplification of chromosome 7p, 8q, 9p, 11q and deletion of
chromosome 8p and 1 of chromosome 7p, 8q, 9p and 11q using Kaplan-Meier estimate with log-rank test.
https://doi.org/10.1371/journal.pone.0174865.g003
Four genetic marker signature of oral squamous cell carcinoma for prognostic significance
PLOS ONE | https://doi.org/10.1371/journal.pone.0174865 April 6, 2017 11 / 21
Discussion
It has been previously noted that the TCGA consortium [19] had conducted the largest
genome-wide profiling study on 172 OSCC samples including oral tongue, buccal mucosa,
alveolar ridge, lip, floor of mouth and hard palate using array CGH technology. In order to val-
idate the CNAs derived from this OSCC cohort, we selected samples from within the oral cav-
ity and excluded oropharynx, hypopharynx, and larynx. We identified 26 amplifications and 3
deletions with a frequency of 8%. Amplifications outnumbered deletions and were noted in
chromosomes 3q, 5p, 7p, 8q, 9p, 10p and 11q while deletions were observed in chromosomes
3p and 8p. This study confirms and adds to the earlier evidence of frequent CNAs among
OSCCs that have been reported in the TGCA and the International Cancer Genome Consor-
tium (ICGC) [19,20]. As depicted in Fig 2, evidence of replicating recurrent CNAs in the pres-
ent research was in agreement with those from ICGC and TGCA projects that could provide
new insights into oral cancer biology.
To the best of our knowledge this is the first study that have identified the presence of one
or more of a group of CNAs (gain 7p, 8q, 11q, and 9p) which function as the novel CNA signa-
ture from array CGH analysis. Interestingly, this CNA signature could serve as a clue to deter-
mine which OSCC patients have a high risk for lymph node metastasis and therefore an
advanced tumor stage. Apart from that, the Kaplan Meier survival curve analysis revealed that
presence of one or more of a group of this CNA signature was significantly associated with
poor prognosis (p< 0.050). Additionally, Multivariate Cox regression model analysis revealed
that this CNA signature group remained as an independent prognostic marker (HRR = 3.455,
95% C1 1.125–10.615, p = 0.026) after adjustment for selected sociodemographic (age, gender,
Fig 4. Concordance percentage for amplification of LRP12 (chr 8q), CCND1 (chr 11q), TPM2 (chr 9p), FSCN1 (chr 7p), EGFR (chr
7p), CLPTM1L (chr 5p) and deletion of CHL1 (chr 3p) and CSMD1 (chr 8p) identified using array CGH and validated using qPCR
copy number analysis in OSCC samples.
https://doi.org/10.1371/journal.pone.0174865.g004
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and risk habits) and clinico-pathological parameters (tumor subsite, tumor differentiation,
tumor size, lymph node status and tumor staging). The qPCR method was used to further vali-
date the CNAs identified from array CGH. Copy number analysis on LRP12, TPM2, EGFR,
FSCN1, CCND1, CLPTM1L, CHL1 and CSMD1 genes were carried out using qPCR. The
rationale of choosing these CNA associated genes was basically due to LRP12, TPM2, EGFR,
Fig 5. Overall survival curves were analyzed according to 1 of genetic marker (EGFR, CCND1, TPM2 and LRP12) using Kaplan-
Meier estimate with log-rank test.
https://doi.org/10.1371/journal.pone.0174865.g005
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Table 4. Multivariate cox regression model analysis of four combined genetic markers consisting of
EGFR, TPM2, CCND1 and LRP12 in OSCC overall survival.
Variables Category No. of patients (%) Multivariate Logistic
regression**
Total 66 HRR 95% CI p value
Four combined genetic
markers
no marker 40 (60.6) 1.00† 0.038
 1 marker 26 (39.4) 2.343 1.047–5.244
Gender Male 24 (36.4) 1.00† 0.508
Female 42 (63.6) 1.4 0.517–3.794
Age (years) < 45 12 (18.2) 1.00† 0.977
 45 54 (81.8) 1.016 0.331–3.119
Smoking No 45 (68.2) 1.00† 0.589
Yes 21 (31.8) 0.744 0.254–2.178
Drinking No 57 (86.4) 1.00† 0.398
Yes 9 (13.6) 1.899 0.429–8.406
Betel quid chewing No 35 (53.0) 1.00† 0.107
Yes 31 (47.0) 2.089 0.852–5.122
Tumour size T1-T2 37 (56.1) 1.00† 0.018
T3-T4 29 (43.9) 3.36 1.23–9.177
Lymph node metastasis Negative 33 (50.0) 1.00† 0.228
Positive 33 (50.0) 1.843 0.682–4.983
pTNM Staging Early 22 (33.3) 1.00† 0.322
Advanced 44 (66.7) 2.27 0.449–
11.484
Differentiation Well 27 (40.9) 1.00† 0.299
Moderate and
poor
39 (59.1) 1.526 0.687–3.388
CI: confidence interval
† Reference category
Significant p—value were highlighted in bold.
**Multivariate logistic regression analysis was applied to adjust the confounders [age, gender, risk habits
(cigarette smoking, betel quid chewing and alcohol drinking)] and clinico-pathologic parameters [tumour
sizes, lymph node metastasis and pathological tumour staging]
https://doi.org/10.1371/journal.pone.0174865.t004
Table 5. Top significant pathways associated with CNAs associated genes.
Ingenuity Canonical Pathways -log(p-
value)
Molecules
ILK Signaling 3.37E00 RELA,SNAI2,CFL1,ACTB,PPP2R5B,ACTN3,VEGFB,VIM,PIK3R4,RICTOR,PPP1R14B,CCND1,
PPP2R3A,RHOD,RHOA,PPM1L,RPS6KA4,PIK3CB,GSK3B,TESK1,ITGB5,MYL3
mTOR Signaling 3.34E00 EIF3H,PPP2R5B,RAC1,VEGFB,EIF3E,PIK3R4,RICTOR,PLD1,FAU,PRKCI,RPS20,EIF3B,
PPP2R3A,RHOD,RHOA,PPM1L,PRKAA1,MRAS,RPS6KB2,PIK3CB,RPS6KA4,RPS3
Tight Junction Signaling 2.68E00 RELA,CLDN11,ACTB,HSF1,PPP2R5B,CLDN18,MARK2,CPSF1,RAC1,PRKAR2A,MYLK,GPAA1,
PRKCI,PPP2R3A,CLDN1,RHOA,PPM1L,PRKAR1B,MYL3
UVA-Induced MAPK Signaling 2.54E00 TIPARP,PARP15,PARP10,RPS6KB2,MRAS,PLCB3,PIK3CB,RPS6KA4,PIK3R4,PARP9,EGFR,
PARP14
Role of CHK Proteins in Cell Cycle
Checkpoint Control
2.53E00 PPP2R3A,RAD9A,PPP2R5B,PPM1L,E2F5,ATR,NBN,RAD1,CDC25A
https://doi.org/10.1371/journal.pone.0174865.t005
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CCND1 being matched with ICGC and TCGA databases whereas FSCN1, CLPTM1L, CHL1
and CSMD1 had been found to be associated with oral cancer [12, 31–33]. This study
attempted to elucidate whether these genes were the driver genes in the CNA regions which is
7p, 5p, 3p and 8p. Thus, the validation of these CNA-associated genes resulted in the identifi-
cation of a “genetic signature” marker. This genetic signature marker contains LRP12,
CCND1, EGFR and TPM2 genes that could predict clinical outcomes and facilitate selection of
therapeutic strategies in oral cancer management that are tailor-made for patients.
CNAs have the tendency to disrupt proto-oncogenes or tumour suppressor genes, and are
known to be major contributors to poor prognosis of oral cancer [7,9,10]. In this current study,
we have identified highly frequent copy number alterations in chromosomes 3p, 3q, 8p, 8q and
11q, as described in previous studies that are capable of leading to poor clinical outcome in
OSCC [10, 13, 23][10,25,26]. Amplification of 8q22.3-q23.1 was the most frequent event in the
current study, and was seen in 18.70% (n = 75) of all OSCCs. Genomic alterations in chromo-
some 8q, especially amplification of 8q22.3-q23.1, have been commonly noted in OSCC [27].
In this current study, amplification of chromosome 8q was found to be significantly related to
advanced pathologic stages in OSCC patients. The plausible reason behind this observation
could be attributed by the presence of the putative oncogene known as LRP12 gene which
belongs to the LDLR superfamily. According to Garnis et al. [34] suggest that this gene plays a
role in oral tumourigenesis and over-expression of this gene is associated with oral cancer.
Losses in 3p26.3-3p26.1 and 3p21.31 were frequently detected and remained as a prognosti-
cator in OSCC cases. These regions harbour the tumour-suppressor gene known as Cell Adhe-
sion Molecule L1 (CHL1), which has been recently shown to contribute in oral tumourigenesis
[10]. Loss of this gene able to arrest both in vitro and in vivo proliferation and invasion of
tumour cells in breast tumourigenesis [28][29].
Both arms of chromosomes 3 and 8 contain several tumour related genes that are involved
in the genesis and progression of oral cancer [8]. Of these, loss in 8p23.32 has been reported
more frequently [8]. In this study, deletion of chromosome 8p was found to be associated with
Table 6. Top significant molecular and cellular functions associated with CNAs involving associated genes.
Molecular and Cellular
Functions
Function annotation p values Molecule Genes
Cell Death and Survival colony survival of cells 1.65E-04 ATR, CA9, CCND1, FANCG, RAD21, RB1CC1, TERC,
TNFSF10
colony survival of tumor cell lines 8.18E-04 CA9, CCND1, FANCG, RAD21, RB1CC1, TERC, TNFSF10
cell viability of fibroblast cell lines 9.69E-04 ATR, CEBPD, FANCG, MUS81, NBN, RAD9A
cell survival of cervical cancer cell lines 3.04E-03 KAT5, RAD21
colony survival of breast cancer cell
lines
3.04E-03 CA9, RB1CC1
Cellular Function and Maintenance colony survival of cells 1.65E-04 ATR, CA9, CCND1, FANCG, RAD21, RB1CC1, TERC,
TNFSF10
colony survival of tumor cell lines 8.18E-04 CA9, CCND1, FANCG, RAD21, RB1CC1, TERC, TNFSF10
autophagy of epithelial cells 3.04E-03 FADD, TNFSF10
colony survival of breast cancer cell
lines
3.04E-03 CA9, RB1CC1
uptake of bacteria 4.96E-03 OTUB1, RAC1, RHOA
Drug Metabolism activation of cytarabine 1.33E-03 ATR, CDC42BPG, NEK11, RPS6KB2, RYK
synthesis of hydrocortisone 1.54E-03 CYP11B1, CYP11B2, RHOA
cleavage of hyaluronic acid 8.80E-03 HYAL1, HYAL2
binding of progesterone 3.94E-02 DNAJA1, STIP1
https://doi.org/10.1371/journal.pone.0174865.t006
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advanced pathologic stage of the tumour. The focal area of 8p23.32 that contained the CUB
and sushi multiple domain protein 1 (CSMD1) genes could be of interest in future investiga-
tions. Deletion and expression loss of this gene have been reported in association with poor
survival, lymph node metastasis and advanced pathologic staging in several cancers [30].
Table 7. Top significant networks and the associated network functions linked with CNAs associated genes.
ID Top Diseases and Functions Score Focus
Molecules
Molecules in Network
1 Cell Death and Survival, Cellular Movement,
Cellular Development
72 86 14-3-3, 26s Proteasome, ACAD9, ACTB, ADRBK1, ANGPT1, ARRB1, ATR,
Actin, Akt, Ap1, BAD, BAG1, BCR(complex), CAMP, CARD11, CARD6,
CASR, CCND1, CD3, CD86, CDC25A, CEBPD, CORO1B, CPNE4, CPT1A,
CRBN, CTTN, CYP11B2, Caspase 3/7, Cdk, Cofilin, Creb, Cyclin A, Cyclin E,
DAB2, DDX58, EGFR, EPPK1, ERK, ERK1/2, F Actin, FADD, FOSL1,
FSCN1, Focal adhesion kinase, GDNF, GPER1, GSK3B, Gsk3, HSF1, Hdac,
Histone h3, Histone h4, Hsp27, Hsp70, Hsp90, IFN Beta, IKK (complex), IL7R,
IgG, Interferon alpha, Jnk, KAT5, LY6K, LYN, MAP2K1/2, MAP3K11,
MAP4K2, MBD4, MME, MST1R, MTORC1, MUS81, MYLK, Mek, Mmp,
NEU3, NFkB (complex), OVOL1, P2RY2, P2RY6, P38 MAPK, PARP, PDGF
BB, PELI3, PI3K (complex), PI3K(family), PIK3CB, PLD1, PLSCR1,
PRKAR2A, PRKCI, PRKDC, PRLR, PTGER4, PTP4A3, Pkc(s), Pld, RAC1,
RASSF1, RB1CC1, RELA, RHOA, RICTOR, RIPK2, RNA polymerase II,
RNF216, RPS3, RUSC2, Rac, Ras, Ras homolog, Rock, SCRIB, SDCBP,
SEMA3B, SHARPIN, SKIL, SKP2, SMARCC1, SNAI2, Shc, Smad2/3, TCR,
TNFSF10, TP63, TRAIP, TRPC1, UBA7, Ubiquitin, VCP, VEGFB, VIM,
VOPP1, Vegf, caspase, estrogen receptor, mir-506, p85 (pik3r)
2 DNA Replication, Recombination, and
Repair, Cancer, Cellular Development
41 63 AIFM1, ALG5, ARHGAP21, ARHGEF26, ATAD2, ATAD3B, Alpha tubulin,
BARD1, BCL6, BLM, BRMS1, C3orf58, C3orf62, C5orf22, CD72, CEP63,
CHCHD6, CNIH2, COX17, CPSF1, CREB5, CSDE1, CTDSPL, CXCL12,
CXCR4, CYP27B1, DCSTAMP, DDIT3, DDX11, DDX54, DEPTOR, DGCR8,
DISC1, DLEU1, DLEU2, DNAJB5, DRAP1, DROSHA, DTX3L, E2F1, E2F8,
E2f, ECT2, EDEM1, EIF3H, EPB41L4AAS1, EXOSC8, FAM162A, FCHSD2,
GINS1, GNA12, GNE, GPAA1, GPSM2, GSR, HIST1H1B, HIST1H2AB,
HIST1H2AG, HIST1H2BJ, HIST1H3B, HSPH1, KANK2, KIAA0196, KIF20A,
KIF22, KLF15, MAFK, MARK2, MCM10, MCM2, MCM4, MCM5, MFAP1,
MGLL, MLH1, MMS22L, MTHFD1, MXD1, MYC, MYO9A, NAA40, NCKIPSD,
NDE1, NDEL1, NDUFB6, NUPR1, PARP10, PARP14, PARP9, PFKFB4,
PITPNM1, POLA2, POLQ, PPFIA1, RAB11FIP5, RACGAP1, RAI14,
RARRES1, RASAL2, RBM14, RCL1, RHOA, RMI2, RNF139, RNF169,
RPL21, RPS16, RPS27, RRM1, RSL1D1, SAMD4A, SHOX2, SIGMAR1,
SKA2, SKP2, SLC25A20, SNRPC, SPIDR, SRGAP2, STAM, TBXA2R,
TESK1, TFDP2, TGM2, TMEM126A, TONSL, TRIB1, TRMT13, TSC22D2,
TUBGCP5, UMPS, USP36, USP8, VHL, WDR76, XRCC2, XRN1, YWHAG,
mir-15, mir-191
3 Cellular Movement, Cell Death and Survival,
Cellular Assembly and Organization
40 62 ABCC4, ACPP, ACSL3, AIMP1, AIMP2, AMOTL2, APLP2, AQP3, AR,
ARHGEF17, ATP1A1, ATP1B3, ATRIP, AUP1, Actin, B4GALT1, BHLHE40,
BUB1, CASP3, CAST, CDC42EP2, CDC42EP4, CDCA5, CDH1, CEL,
CENPE, CLCA2, CLRN1, CNBP, COL18A1, CSPG4, DAG1, DARS,
DHCR24, DNAJC13, DSE, Dynein, EEF1D, EEF1G, ELK3, EPB41, ERBB2,
ESPL1, FANCG, FASN, FAU, FEN1, FKBP4, FNDC3B, FOXA1, FOXH1,
FSTL1, GLIPR2, GNAI2, GNB2, GPI, HGF, HLTF, HUS1, HYAL1, ITGB5,
KDELR2, KDM4B, KIF22, KPNA1, LIG1, LMBRD2, LRIG1, LTBP3, MAD2L2,
MMP16, MSX2, Mre11, NBN, NKX3-1, NPR3, PDGFA, PDIA5, PFN1, PGK1,
PKD1, PLCD1, PLEC, PLXDC2, PMEPA1, PODXL, PPID, PRSS3, PSENEN,
PTPN23, PTPRF, RAD1, RAD17, RAD9A, RAD9B, RAP2B, RHOD, RNA
polymerase I, RNF7, ROR1, RORA, RPA, RPL8, RPN1, RPS16, RPS20,
RPS3, RPS3A, Rac, Rnr, SCAP, SEC61A1, SEMA3F, SFRP4, SLC12A6,
SLC16A1, SLC3A2, SNX1, SNX2, SNX32, SSH2, SSH3, STT3B, SYVN1,
Secretase gamma, TARS, TF, TMEM74, TNFRSF12A, TOPBP1, TOPORS,
TOX, TPD52, URI1, UXT, VARS, VIM, YWHAB, ZNF148, miR-1285-3p (and
other miRNAs w/seed CUGGGCA)
https://doi.org/10.1371/journal.pone.0174865.t007
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Amplification in 11q13.3 was associated with advanced stage of the tumour in OSCC. It has
been well-established that chromosome 11q has cancer-related genes that play an important
role in tumourigenesis [31,32]. Cancer-related genes including ANO1, CCND1, CTTN,
FADD and ORAOV1 are involved in tumour cell proliferation, evasion of apoptosis, invasion,
and migration [33–37]. The amplification of 11q13 has been related with poor clinical out-
come [38] and metastasis in head and neck cancer [39]. This data reflects the great value of
this region as being a valuable biomarker in the prognosis and treatment planning of oral
cancers.
Amplification in 7p12-22 has been identified in almost 30% of OSCCs and more than 40%
of HNSCC samples from TCGA [25, 35]. We found that amplification in 7p is associated with
tumour size (T3-T4) and advanced pathologic staging among OSCCs. Among the candidate
oncogenes harbored in this region such as EGFR, TWIST1, and HOXA genes, EGFR has
shown a high level of amplification in the OSCC samples of the TCGA project [25]. In this
study, amplification in 9p21.1–13.3 was identified in 14.7% of OSCC samples.
Amplification of 9p, especially 9p13, has been frequently reported in OSCC, contributing to
early stages of oral tumourigenesis [10, 36]. This current study also revealed that amplification
of 9p was significantly associated with lymph node metastasis that might be driven by proto-
oncogenes such as CA9, VCP, DCTN3, and STOML2. Towle et al. [36] demonstrated that the
inhibition of these putative genes in OSCC cell lines suppressed tumour cell proliferation, sug-
gesting that amplification of 9p13 is more likely to contribute in the aggressiveness of multiple
oncogenes in oral tumourigenesis.
Various studies have employed pathway and network analyses to filter the driver genes in
signaling pathways and cancer-related gene networks from the robust cancer data sets [37–
39]. In this study, several oncogenic signaling pathways were identified using the IPA pathway
analysis. The most significant signaling pathway was associated with Integrin-linked kinase
(ILK) signaling. Integrin-linked kinase, a candidate oncogene, acts as a multifunctional serine/
threonine kinase. Activation of this gene results in cell proliferation, evasion of apoptotic sig-
nals and metastasis [40]. Recently, Que et al. [40] showed that targeting the ILK signalling
pathway would suppress tumour cell proliferation, the adhesion and invasion ability in oral
tumourigenesis and inhibit tumour growth, invasion, and metastasis in the in vivo model.
These findings highlight that the ILK signalling pathway plays a novel role in oral tumourigen-
esis by regulating EMT associated genes and other downstream targets in this pathway. The
IPA analysis also showed that the biological functions related to the CNAs associated genes
included cell death and survival, cellular function and maintenance, cellular development, cel-
lular growth and proliferation, and cellular movement. All these hallmark cancer-associated
functions are well-documented by Douglas Hanahan and Robert Weinberg in their review
paper [41]. The identification of the CCND1, an amplified gene harboured in 11q13.3, was
involved in all of the findings and implies that its over-expression would lead to the character-
istics of cancers by promoting the proliferation, migration, and invasion of tumour cells and
the evasion of apoptosis signals in oral tumourigenesis.
The IPA network analysis revealed that a a novel network was related to cell death and sur-
vival, cellular movement and cellular development. Within this network, several genes were
identified namely CCND1, RELA, TP63, and EGFR as being major contributors to tumour
cell proliferation, immortalization, and metastasis in oral tumourigenesis. The interaction net-
work between these four candidate oncogenes namely CCND1, RELA, TP63, and EGFR have
been associated with several oncogenic pathways which are the PI3 Kinase/Akt signalling, NF-
κB signalling, cell cycle control signalling, and MAPK/Erk ingrowth and differentiation signal-
ling pathways. Overall, these oncogenic pathways cross-regulate each other and are regulated
by EGFR, ERK, and Akt phosphorylation, forming an important network that enhances tumor
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cell activities such as evasion of apoptosis, immortalization, proliferation and metastasis in
tumorigenesis.
In summary, this study has recognized several CNAs that are associated with oral tumori-
genesis. This study also demonstrated the significant association between amplification of
chromosome 8q, 11q, 7p and 9p and deletion of 8p with clinico-pathologic parameters such as
the size of the tumour, metastatic lymph nodes and pathological stage in OSCC. Furthermore,
co-amplification of the four chromosomes 7p, 8q, 9p, 11q that function as a CNA signature
and the genetic markers (CCND1, EGFR, LRP12 and TPM2) remained as independent prog-
nosticators in OSCC for predicting disease outcome. Apart from that, this research detected
several copy number changes that are related with pivotal biological networks which often dis-
rupt oral tumorigenesis in different oncogenes associated with CNAs. This research will pro-
vide an enhanced appreciation of the CNAs in OSCC and will add to the growing body of
knowledge that these pathways/networks play in oral tumorigenesis.
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